OS Therapies Inc OSTX
OS Therapies Inc (NYSE: OSTX) is an oncology drug developer. Its lead program, OST-HER2 (OST31-164), is in Phase 2 for Recurrent, fully resected pulmonary metastatic osteosarcoma. Its next catalyst on record is OST-HER2 (Herlystic): UK MHRA conditional marketing authorization application submission targeted early Q4 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: OST-HER2 (Herlystic) — UK MHRA conditional marketing authorization application submission targeted early Q4 2026. (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| OST-HER2 (OST31-164) | Recurrent resected pulmonary metastatic osteosarcoma (Phase IIb complete, fully enrolled; rolling BLA/conditional MAA in progress) | vaccine | Phase 2 |
| OST-tADC (tunable antibody-drug conjugate platform) | Solid tumors | antibody | Pre-clinical |
| ADXS-503 / ADXS-504 (Lm platform assets acquired from Ayala) | — | vaccine | Pre-clinical |
Recent results and decisions
- Oct 15, 2026n/a OS Therapies completed initial closing of warrant exercise inducement, receiving gross proceeds of approximately $7.2 million as seven holders exercised or pre-funded Existing Warrants to purchase 5,517,253 shares at a reduced exercise price of $1.30 per share.
At the initial closing, seven Holders exercised, or pre-funded the exercise of, Existing Warrants to purchase an aggregate of 5,517,253 shares of common stock, resulting in a total of $7.2 million in gross proceeds to the Company.
Filing - Apr 30, 2026accepted EMA (ex-US) initiated rolling review of the OST-HER2 conditional marketing authorization application.
has initiated Continuous Evaluation (“Rolling Review”) of the OST-HER2 Conditional Marketing Authorisation (CMA) request regulatory dossier for the prevention of recurrence in fully resected, pulmonary metastatic osteosarcoma.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.